Novacyt ( (FR:ALNOV) ) has provided an announcement.
Novacyt S.A. has provided its monthly update on the Liquidity Agreement with Invest Securities SA, detailing the trading of its ordinary shares. During February 2025, Invest Securities purchased and sold shares within specified price ranges, resulting in 73,122 shares held in treasury. The total number of ordinary shares stands at 70,626,248, which shareholders can use for interest calculations. This update reflects Novacyt’s ongoing efforts to manage its share liquidity and maintain transparency with stakeholders, potentially impacting shareholder decisions and market perceptions.
More about Novacyt
Novacyt is an international molecular diagnostics company that offers a wide range of integrated technologies and services focused on genomic medicine. The company develops, manufactures, and commercializes molecular assays and instrumentation, providing end-to-end solutions across human health, animal health, and environmental sectors. Novacyt operates through three business segments: Clinical, Instrumentation, and Research Use Only, and has a global commercial presence in over 65 countries. It is listed on the London Stock Exchange’s AIM market and the Paris Stock Exchange Euronext Growth.
Average Trading Volume: 291
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $43.93M
Learn more about ALNOV stock on TipRanks’ Stock Analysis page.